A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Guadecitabine (Primary) ; Azacitidine; Cytarabine; Decitabine
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ASTRAL-1
- Sponsors Astex Pharmaceuticals; Otsuka Pharmaceutical
- 22 Dec 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 22 Dec 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.
- 21 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.